Bullish & Foolish
Full KYNB fundamentals All 466 on the Survival Watch

KYNBKYNTRA BIO, INC.

Is Kyntra Bio struggling financially?

Yes, by its own account. Kyntra Bio told the SEC on 10 Nov 2025, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Nov 2025

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$30.4M
Source filing
10-Q 10 Nov 2025
Balance sheet
30 Jun 2026

Cash runway

  • 25months

    If the burn speeds up

    Empty by Jul 2028

  • 35months

    If it eases off

    Empty by May 2029

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$91.3M

÷

Cash burned over the last 12 months

$36.6M

What Kyntra Bio told the SEC

…Company’s senior secured term loan facilities with Morgan Stanley Tactical Value (“MSTV”) would become immediately due and payable. These factors had raised substantial doubt about the Company’s ability to continue as a going concern. On August 29, 2025, u pon the Transaction close, the Company received cash for the sale of $ 210.4 million and repaid its senior secured term loan facilities with MSTV, outstanding…

KYNTRA BIO, INC., Form 10-Q, filed 10 Nov 2025.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 70% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt